Compare Cytokinetics Inc (CYTK) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Paycom Software Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Paycom Software Inc trades at $140.81 (market cap $6.70B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Paycom Software Inc pays a 1.04% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PAYC | |
|---|---|---|
Market Cap | $11.12B | $6.70B |
Sector | Technology | Technology |
52-Week High | $87.26 | $238.80 |
52-Week Low | $33.23 | $113.59 |
Enterprise Value | $11.59B | $7.31B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Paycom Software (PAYC) trades at $146.50, up 5.34% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 22.44% net income margin and 37.15% ROE, though Q2 2026 earnings are pending. Recent news highlights product innovation with the launch of Asset Management tool and board appointments, supporting growth prospects in the HCM software sector.
Outlook remains positive with analyst consensus price target of $151 suggesting modest upside, balanced by high valuation multiples and competitive pressures. Key risks include execution challenges in maintaining growth momentum and sensitivity to economic cycles affecting HR software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
